Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Shanghai Haixin Group Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 5/6
Shanghai Haixin Group has been growing earnings at an average annual rate of 7.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 3.8% per year. Shanghai Haixin Group's return on equity is 4.9%, and it has net margins of 17.2%.
Anahtar bilgiler
7.4%
Kazanç büyüme oranı
7.4%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 10.9% |
| Gelir büyüme oranı | 3.8% |
| Özkaynak getirisi | 4.9% |
| Net Marj | 17.2% |
| Sonraki Kazanç Güncellemesi | 30 Oct 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Earnings Not Telling The Story For Shanghai Haixin Group Co., Ltd. (SHSE:600851) After Shares Rise 26%
Oct 01
Shanghai Haixin Group's (SHSE:600851) Profits May Not Reveal Underlying Issues
Aug 30Shanghai Haixin Group (SHSE:600851) Has A Pretty Healthy Balance Sheet
Aug 22Shanghai Haixin Group Co., Ltd. (SHSE:600851) Investors Are Less Pessimistic Than Expected
Aug 01Gelir ve Gider Dağılımı
Shanghai Haixin Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 964 | 166 | 408 | 24 |
| 31 Mar 24 | 1,109 | 172 | 438 | 23 |
| 31 Dec 23 | 1,183 | 166 | 456 | 23 |
| 30 Sep 23 | 1,338 | 120 | 474 | 22 |
| 30 Jun 23 | 1,429 | 141 | 513 | 23 |
| 31 Mar 23 | 1,420 | 163 | 548 | 22 |
| 31 Dec 22 | 1,440 | 164 | 578 | 22 |
| 30 Sep 22 | 1,465 | 153 | 639 | 23 |
| 30 Jun 22 | 1,381 | 140 | 630 | 22 |
| 31 Mar 22 | 1,560 | 136 | 647 | 25 |
| 31 Dec 21 | 1,511 | 132 | 653 | 24 |
| 30 Sep 21 | 1,290 | 148 | 648 | 23 |
| 30 Jun 21 | 1,272 | 144 | 599 | 24 |
| 31 Mar 21 | 1,002 | 130 | 546 | 21 |
| 31 Dec 20 | 933 | 119 | 464 | 22 |
| 30 Sep 20 | 980 | 129 | 437 | 21 |
| 30 Jun 20 | 1,037 | 126 | 438 | 20 |
| 31 Mar 20 | 1,072 | 94 | 462 | 20 |
| 31 Dec 19 | 1,112 | 104 | 481 | 20 |
| 30 Sep 19 | 1,168 | 127 | 415 | 18 |
| 30 Jun 19 | 1,113 | 126 | 415 | 16 |
| 31 Mar 19 | 1,115 | 140 | 370 | 17 |
| 31 Dec 18 | 1,099 | 135 | 376 | 16 |
| 30 Sep 18 | 1,066 | 113 | 421 | 14 |
| 30 Jun 18 | 1,044 | 123 | 390 | 21 |
| 31 Mar 18 | 1,024 | 113 | 366 | 16 |
| 31 Dec 17 | 1,000 | 105 | 334 | 13 |
| 30 Sep 17 | 1,014 | 26 | 329 | 10 |
| 30 Jun 17 | 1,012 | 31 | 323 | 0 |
| 31 Mar 17 | 997 | 91 | 315 | 0 |
| 31 Dec 16 | 1,012 | 90 | 304 | 0 |
| 30 Sep 16 | 1,001 | 189 | 290 | 0 |
| 30 Jun 16 | 1,058 | 180 | 289 | 0 |
| 31 Mar 16 | 1,069 | 153 | 281 | 0 |
| 31 Dec 15 | 1,052 | 157 | 282 | 0 |
| 30 Sep 15 | 1,096 | 296 | 296 | 0 |
| 30 Jun 15 | 1,094 | 369 | 293 | 0 |
| 31 Mar 15 | 1,099 | 327 | 291 | 0 |
| 31 Dec 14 | 1,110 | 291 | 293 | 0 |
| 30 Sep 14 | 1,166 | 131 | 306 | 0 |
| 30 Jun 14 | 1,215 | 35 | 305 | 0 |
| 31 Mar 14 | 1,243 | 0 | 305 | 0 |
| 31 Dec 13 | 1,262 | 65 | 301 | 0 |
Kaliteli Kazançlar: 600851 has high quality earnings.
Büyüyen Kar Marjı: 600851's current net profit margins (17.2%) are higher than last year (9.8%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 600851's earnings have grown by 7.4% per year over the past 5 years.
Büyüme Hızlandırma: 600851's earnings growth over the past year (18.2%) exceeds its 5-year average (7.4% per year).
Kazançlar vs. Sektör: 600851 earnings growth over the past year (18.2%) exceeded the Pharmaceuticals industry -0.6%.
Özkaynak Getirisi
Yüksek ROE: 600851's Return on Equity (4.9%) is considered low.